一組癌癥和影像學專家組成的國際小組，制定了一項評估淋巴瘤治療反應的標準指南。該指南將為全球范圍的臨床醫(yī)生提供統(tǒng)一標準，用以比較和解釋淋巴瘤治療的臨床試驗，從而推動新治療措施的開發(fā)。

該新指南是由國際統(tǒng)一標準化項目(IHP)研發(fā)的，是根據1999年由包括臨床醫(yī)生、放射科醫(yī)生和病理學家組成的國際工作小組(IWG)制定的非何杰金淋巴瘤治療反應評估標準而制定的。

PET是一種非侵入性影像技術，該技術利用了注射的化學示蹤劑發(fā)射出的放射活性。PET使用的放射示蹤劑最典型的是氟脫氧葡萄糖(FDG)，這是葡萄糖的放射性標記形式，該物質主要被腫瘤而不是正常組織所利用。

Guidelines Add PET for Evaluating Lymphoma Treatment
 
An international team of cancer and imaging specialists has developed standardized guidelines for assessing lymphoma response to treatment. The guidelines will provide clinicians worldwide with uniform criteria to compare and interpret clinical trials of lymphoma treatments and should facilitate the development of new therapies.

The new guidelines, developed by the International Harmonization Project (IHP), build on criteria for treatment response assessment of non-Hodgkin’s lymphoma published in 1999 by an international working group (IWG) of clinicians, radiologists, and pathologists.

PET is a non-invasive imaging technique that uses radioactivity emitted from injected tracer chemicals to measure and image biologic activity. The most typically used PET radiotracer is fluorodeoxyglucose (FDG), a radiolabeled form of glucose, which is consumed more avidly by tumors than by healthy tissue.